Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma

BRAFV600 mutations in melanoma are targeted with mutation-specific BRAF inhibitors in combination with MEK inhibitors, which have significantly increased overall survival, but eventually lead to resistance in most cases. Additionally, targeted therapy for patients with NRASmutant melanoma is difficu...

Full description

Bibliographic Details
Main Authors: Alexander Schulz, Jennifer Raetz, Paula C. Karitzky, Lisa Dinter, Julia K. Tietze, Isabell Kolbe, Theresa Käubler, Bertold Renner, Stefan Beissert, Friedegund Meier, Dana Westphal
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
melanoma
resistance
BRAF
MEK
encorafenib
vemurafenib
Online Access:https://www.mdpi.com/2072-6694/14/19/4930

Internet

https://www.mdpi.com/2072-6694/14/19/4930

Similar Items